To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC22567 | Sulfatinib Featured |
Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC50 of 2/24/1 nM, 15 nM, 4 nM, respectively.
More description
|
|
| DC20393 | Golgicide A Featured |
Golgicide A is a potent, highly specific, reversible inhibitor of the cis-Golgi ArfGEF GBF1, inhibits the effect of shiga toxin on protein synthesis with IC50 of 3.3 uM.
More description
|
|
| DC60077 | JUN76288 Featured |
JUN76288, also known WEE1-IN-3, is a potent WEE1 kinase inhibitors useful in treatment of cancer and other proliferative diseases. This product has no formal name at the moment. For the convenience of communication, a temporary code name was therefore proposed according to MedKoo Chemical Nomenclature
More description
|
|
| DC44110 | β-Lactamase-IN-2(UUN51204;Schembl20899335) Featured |
β-Lactamase-IN-2 is a beta-lactamase inhibitor, extracted from patent WO 2019075084 A1, compound 1. β-Lactamase-IN-2 has anti-microbial and anti-bacterial effects.
More description
|
|
| DC9467 | Epinastine Featured |
Epinastine(WAL801) is an antihistamine and mast cell stabilizer that is used in eye drops to treat allergic conjunctivitis.
More description
|
|
| DC44514 | MR837(ZINC30303842) Featured |
MR837 is an inhibitor of NSD2-PWWP1. MR837 can bind with human nuclear receptor binding SET domain protein 2 (PWWP domain).
More description
|
|
| DC44214 | CC-90001 Featured |
CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis.
More description
|
|
| DC58063 | HG106 Featured |
HG106 is a potent SLC7A11 inhibitor and enhances ROS generation, ER stress, and ultimately growth arrest specifically in KRAS-mutant lung adenocarcinoma (LUAD).
More description
|
|
| DC46184 | YUM70 Featured |
YUM70 is a potent inhibitor of glucose-regulated protein 78 (GRP78) inhibitor with an IC50 of 1.5 μM. YUM70 induces endoplasmic reticulum (ER) stress-mediated apoptosis in pancreatic cancer.
More description
|
|
| DC44603 | QQN52061 Featured |
QQN52061 is GPR34 receptor modulator, which can control function of GPR34 receptor (as antagonist or inverse agonist). QQN52061 was first reported in PCT Int. Appl. (2006), WO 2006088246. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature .
More description
|
|
| DC60083 | ZINC77292789(Fmoc-Thr(galnac(Ac)3-alpha-D)-OH) Featured |
ZINC77292789 is a reagent for making synthetic MUC1 Glycopeptide Bearing βGalNAc-Thr as a Tn Antigen Isomer Induces the Production of Antibodies against Tumor Cells. ZINC77292789 was a starting material to make trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
More description
|
|
| DC60084 | OVN73571 Featured |
OVN73571, also known as Fmoc-Ser[GalNAc(Ac)3-α-D]-OH, is a useful chemical intermediate for synthesis of Tn/T Antigen MUC1 Glycopeptide BSA Conjugates, which can use used as Vaccines. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS.
More description
|
|
| DC8639 | Z-VAD(OH)-FMK Featured |
Z-VAD(OH)-FMK is an irreversible tripeptide inhibitor of all caspases.
More description
|
|
| DC7181 | KPT-276 Featured |
KPT-276, analog of KPT-185, is an orally bioavailable selective inhibitors of nuclear export (SINE) that irreversibly bind to CRM1 and block the function of CRM1.
More description
|
|
| DC60086 | Lasmiditan HCl Featured |
Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. Lasmiditan showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo.
More description
|
|
| DC60087 | Boc-Gly-Gly-Phe-Gly-OH Featured |
Boc-Gly-Gly-Phe-Gly-OH is a protease cleavable linker used for the antibody-drug conjugate (ADC).
More description
|
|
| DC29027 | MC-Gly-Gly-Phe Featured |
MC-Gly-Gly-Phe is a cleavable linker used for antibody-drug conjugates (ADC).
More description
|
|
| DC60088 | SIN44126 Featured |
SIN44126 is a IRAK4 inhibitor, which was first described in patent WO 2015104688. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature .
More description
|
|
| DC60089 | GUN30820 Featured |
GUN30820, also known as Brr2 inhibitor C9 or Brr2 Inhibitor 9, is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa a group of progressive retinal degenerative disorders. GUN30820 was first described in Journal of Medicinal Chemistry (2017), 60(13), 5759-5771. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature
More description
|
|
| DC43995 | Conoidin A Featured |
Conoidin A is a cell permeable inhibitor of T. gondii enzyme peroxiredoxin II (TgPrxII). Conoidin A covalently binds to the peroxidatic Cys47 of TgPrxII, irreversibly inhibiting its hyperperoxidation activity with an IC50 of 23 µM. Conoidin A also inhibit
More description
|
|
| DC60091 | KUN56321 Featured |
KUN56321 is a luminescent agent. The application of KUN56321 comprises: coating the film of KUN56321 onto hole transport layer or electron transport layer of ITO glass by vacuum evapn., coating the hole transport layer or electron transport layer onto the film by evapn., prepg. metal electrode by evapn. KUN56321 showed the capability to improve light emitting efficiency and reducing drive voltage in org. light-emitting device and display device. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature .
More description
|
|
| DC57040 | EUK-134 Featured |
EUK-134 is an antioxidant compound with superoxide dismutase and catalase activity for oxidative species such as peroxynitrite, superoxide, and hydrogen peroxide.
More description
|
|
| DC60092 | DWN63831 Featured |
DWN63831 is a lysyl oxidase inhbitor. DWN63831 may be useful in treatment of a variety of disorders, e.g., fibrosis, cancer and angiogenesis in human subjects as well as in pets and livestock. DWN63831 was first reported in patent WO 2020024017.
More description
|
|
| DC46158 | CAY10698 Featured |
CAY10698 (compound 1) is a potent and selective inhibitor of 12-Lipoxygenase (12-LOX) with an IC50 of 5.1 μM. CAY10698 is inactive against 5-LOX, 15-LOX-1, 15-LOX-2 and COX-1/2.
More description
|
|
| DC7849 | DTP3 Featured |
For the detailed information of DTP3, the solubility of DTP3 in water, the solubility of DTP3 in DMSO, the solubility of DTP3 in PBS buffer, the animal experiment (test) of DTP3, the cell expriment (test) of DTP3, the in vivo, in vitro and clinical trial test of DTP3, the EC50, IC50,and affinity,of DTP3, Please contact DC Chemicals..
More description
|
|
| DC60094 | Val-Lys(Boc)-PAB Featured |
Val-Lys(Boc)-PAB is a ADC linker. Val-Lys(Boc)-PAB was used to prepare camptothecin peptide conjugates as antitumor agents (WO 2019195665). It was used as a non-linear self-immolative linker for reducing hydrophobicity of antibody-drug conjugates for cancer therapy (WO 2018069375).
More description
|
|
| DC20008 | PI3Kδ-IN-1 Featured |
PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM.
More description
|
|
| DC43994 | SMS2-IN-1 Featured |
SMS2-IN-1 is a potent and highly selective sphingomyelin synthase 2 (SMS2) inhibitor with an IC50 of 6.5 nM and a Kd of 37 nM. SMS2-IN-1 shows 150-fold selectivity for SMS2 over SMS1 (IC50 of 1000 nM).
More description
|
|
| DC60095 | NV-5138 Featured |
NV-5138 is an orally and centrally active small-molecule drug for the treatment of major depressive disorder (MDD). It directly and selectively activates the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway by binding to and modulating sestrin2, a leucine amino acid sensor and upstream regulatory pathway. The mTORC1 pathway is the same signaling pathway that the NMDA receptor antagonist ketamine activates in the medial prefrontal cortex (mPFC) to mediate its rapid-acting antidepressant effects. A single oral dose of NV-5138 has been found to increase mTORC1 signaling and produce synaptogenesis in the mPFC and to induce rapid antidepressant effects in multiple animal models of depression.
More description
|
|
| DC44722 | NSC-92828 Featured |
NSC-92828, also known as 3-Phenanthrenebutyric acid, is a Protein–protein interaction inhibitor (2P2 inhibitor or 2P2I). Protein–protein recognition is the cornerstone of multiple cellular and pathological functions. Therefore, protein–protein interaction inhibition (2P2I) is endowed with great therapeutic potential despite the initial belief that 2P2I was refractory to small-molecule intervention.
More description
|
|